Colestilan chloride
- Generic Name
- Colestilan chloride
- Drug Type
- Small Molecule
- CAS Number
- 95522-45-5
- Unique Ingredient Identifier
- VSI302RYSR
- Background
Colestilan is an ingredient in the EMA-withdrawn product BindRen.
- Associated Conditions
- Hyperphosphataemia
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
Phase 1
Completed
- Conditions
- HyperphosphatemiaChronic Kidney Disease
- Interventions
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT01976572
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, Springfield House Hyde Street, United Kingdom
Safety and Tolerability Study of MCI-196
Phase 3
Terminated
- Conditions
- HyperphosphatemiaChronic Kidney DiseaseNot on DialysisPaediatric
- Interventions
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 4
- Registration Number
- NCT01818687
- Locations
- 🇬🇧
Investigational site, London, United Kingdom
Long-term Extension Study of MCI-196
Phase 3
Terminated
- Conditions
- PaediatricDialysisHyperphosphatemiaChronic Kidney Disease
- Interventions
- Drug: CBPB
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT01814917
- Locations
- 🇬🇧
Investigational site, London, United Kingdom
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
Phase 3
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 260
- Registration Number
- NCT00858637
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT00772382
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Phase 3
Completed
- Conditions
- Chronic Kidney DiseaseDialysisHyperphosphatemia
- Interventions
- Drug: Another Phosphate binder (Sevelamer)
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 632
- Registration Number
- NCT00542815
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
Phase 3
Completed
- Conditions
- DialysisHyperphosphatemiaDyslipidemiaChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 642
- Registration Number
- NCT00542386
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
Phase 3
Completed
- Conditions
- Chronic Kidney DiseaseHyperphosphatemiaDialysis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 245
- Registration Number
- NCT00506441
Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 183
- Registration Number
- NCT00497198
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath